With the current guidelines recommending SGLT2i, or GLP-1 RA if intolerance or contraindication to SGLT2i, as an addition to other glucose lowering medications in people with diabetes and cardiovascular disease, multiple cardiovascular risk factors and/or kidney disease [31], uptake of SGLT2i and GLP-1 RA for people with diabetes and at high cardiovascular risk should improve in clinical practice. This evidence concerns the gene GLP1R and cardiovascular disorder.